Clinical findings with the oral contraceptive combination ethinylestradiol/dienogest in the Czech Republic

Methods and Findings in Experimental and Clinical Pharmacology

Volumn 24, Issue 10, 2002, Pages 689-696

  Golbs, Siegfried ^a   Domhardt, R ^a   Presl, J ^b   Ganev, M ^b   Wisser, K H ^a   Zimmermann, T ^a  

^a BAYER PHARMA AG   (Germany)

^b Schering Office   (Czech Republic)

Author keywords

Antiandrogenic action; Combined oral contraceptives; Contraceptive efficacy; Dienogest; Ethinylestradiol; Progestogen

Indexed keywords

CONTRACEPTIVE AGENT; DIENOGEST PLUS ETHINYLESTRADIOL; GESTAGEN;

ACNE VULGARIS; ADULT; ARTICLE; BREAKTHROUGH BLEEDING; BREAST TENDERNESS; CHLOASMA; CHOLESTASIS; CLINICAL TRIAL; CONTRACEPTION; CZECH REPUBLIC; DRUG ACTIVITY; DRUG EFFICACY; DRUG SAFETY; DYSMENORRHEA; FEMALE; HAIR; HEADACHE; HEARING DISORDER; HEPATITIS; HUMAN; HYPERTENSION; INCIDENCE; JAUNDICE; LIVER TUMOR; LOW DRUG DOSE; MENSTRUATION; MULTICENTER STUDY; OVULATION; PHASE 3 CLINICAL TRIAL; PHLEBITIS; PREGNANCY; PROSPECTIVE STUDY; PRURITUS; SEIZURE; SIDE EFFECT; THROMBOEMBOLISM; VISUAL DISORDER;

ADOLESCENT; ADULT; BREAST DISEASES; CONTRACEPTIVES, ORAL, COMBINED; CYTOCHROME P-450 CYP1A1; DEPRESSION; DRUG ADMINISTRATION SCHEDULE; FEMALE; GASTROINTESTINAL DISEASES; HEADACHE; HUMANS; NANDROLONE; PROSPECTIVE STUDIES; SKIN DISEASES; STEROID HYDROXYLASES; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 0036982604     PISSN: 03790355     EISSN: None     Source Type: Journal    
DOI: 10.1358/mf.2002.24.10.802320     Document Type: Article

References (22)

1. Oettel, M., Holz, C. Hybrid progestins - the example of dienogext. In: Progestins and Antiprogestins in Clinical Practice. Sitruc-Ware. R., Mishell, D. (Eds.). Marcel Dekker Inc.: New York 2000, 163-78.
2. Oettel, M., Carol, W., Elger, W. et al. A 19-norprogestin without a 17α-ethinyl group. II: Dienogest from a pharmacodynamic point of view. Drugs Today 1995, 31: 517-36.
3. Oettel, M., Breitbarth, H., Elger, W. et al. The pharmacological profile of dienogest. Eur J Contraception Reprod Health Care 1998. 3: 1-12.
4. Stanczyk, F.Z. Introduction: Structure-function relationships, metabolism, pharmacokinetics and potency of progestins. Drugs Today 1996, 32: 1-14.
5. Oettel, M., Gräser, T., Hoffmann, H. et al. The preclinical and clinical profile of dienogest. A short overview. Drugs Today 1999, 35 (Suppl. C): 3-12.
6. Oettel, M., Carol, W., Gräser, T. et al. Der Einfluss einer Ethinylestradiol-Dienogest-Kombination auf die Serum-Androgen-Konzentration. Zentralbl Gynäkol 1997, 119: 597-606.
7. Moore, C., Luderschmidt, C., Moltz, L. et al. Antiandrogenic properties of the dienogest-containing oral contraceptive Valette®. Drugs Today 1999, 35 (Suppl. C): 69-78.
8. Golbs, S., Nikolov, R., Zimmermann, T. Pharmacology of nortestosterone derivatives. Menopause Rev 2001, 6: 29-44.
9. Luderschmidt, C. Hormonal control of androgenic disorders in women. In: Extragenital Effects of Oral Contraceptives. Elstein M. (Ed.). The Parthenon Publishing Group: Carnforth 1997, 45-51.
10. Zimmermann, T., Wisser, K.-H., Dietrich, H. The effects of Valette® on skin and hair: Results of a post-marketing surveillance study. Int J Clin Pract 2000, 54: 85-91.
11. Moore, C., Feichtinger, W., Klinger G. et al. Clinical findings with the dienogest-containing oral contraceptive Valette®. Drugs Today 1999, 35 (Suppl. C): 53-68.
12. Zimmermann, T., Dietrich, H., Wisser K.-H., Hoffmann, H. Efficacy, and tolerability, of the dienogest-containing oral contraceptive Valette®: Results of a postmarketing surveillance study. Drugs Today 1999, 35 (Suppl. C): 79-87.
13. Wiegratz, I., Lee, J.H., Kutschera, E. et al. Effect of dienogest-containing oral contraceptives on lipid metabolism. Contraception 2002, 65: 223-9.
14. Fotherby, K. Clinical experience and pharmacological effects of an oral contraceptive containing 20 μg oestrogen. Contraception 1992, 46: 477-88.
15. Fotherby, K. Twelve years of clinical experience with an oral contraceptive containing 30 μg ethinyloestradiol and 150 μg desogestrel. Contraception 1995, 51: 3-12.
16. Archer, D.F., Maheux, R., DelConte, A., O'Brien, F.B. A new low-dose monophasic combination oral contraceptive (Alesse®) with levonorgestrel 100 micrograms and ethinyl estradiol 20 micrograms. North American Levonorgestrel Study Group (NALSG). Contaception 1997, 55: 139-44.
17. Brill, K. Minimizing the problem of poor compliance in adolescents. Clinical experience with a modern low-dose gestodene-containing oral contraceptive. Ann NY Acad Sci 1997, 816: 457-65.
18. Jones, E. E. Androgenic effects of oral contraception: Implications for patient compliance. Am J Med 1995, 98: 116-119S.
19. Serfaty, D. Medical aspects of oral contraceptive discontinuation. Adv Contracept 1992, 8 (Suppl. 1): 21-33.
20. Zimmermann, T., Wisser, K.-H., Dietrich, H. Effects of the dienogest-containing oral contraceptive Valette® on skin and hair. Results of a postmarketing surveillance study. Drugs Today 1999, 35 (Suppl. C): 97-104.
21. Rekers, H. Multicenter trial of a monophasic oral contraceptive containing ethinyl estradiol and desogestrel. Acta Obstet Gynecol Scand 1988, 67: 171-4.
22. Fuchs, N., Duesterberg, B., Weber-Diehl, F. et al. The effect on blood pressure of a monophasic oral contraceptive containing ethinylestradiol and gestodene. Contraception 1995, 51: 335-9.